To fight against novel coronavirus pandemic, India plans to vaccinate all its citizens by December, according to the top official of the central government. Around 216 crore vaccine doses would become available between August and December, Dr Vinod Kumar Paul, member of Niti Ayog said on Thursday.
Biological E, India’s oldest private vaccine maker would supply 30 crore doses of its COVID-19 vaccine candidate between August to December this year, according to ministry of health and family welfare. In April, the Hyderabad-based pharma giant received an approval to start the phase III clinical trial of its recombinant protein vaccine candidate in India. It has already completed the phase I and phase II clinical trials of its COVID-19 vaccine in the country.
Biological E’s sub unit vaccine, modelled after the hepatitis B vaccine, uses traditional protein-based vaccine platforms. The vaccine candidate “includes an antigen developed by Texas Children’s Hospital Center for Vaccine Development and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team and Dynavax Technologies Corporation’s advanced adjuvant CpG 1018TM.”
